SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Raskind, W. H. Articles by Ochs, H. D. Search for Related Content PubMed PubMed Citation Articles by Raskind, W. H. Articles by Ochs, H. D. Related Collections Hematopoiesis and Stem Cells Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 95 No. 7 (April 1), 2000: pp. 2262-2268 HEMATOPOIESIS Mapping of a syndrome of X-linked thrombocytopenia with thalassemia to band Xp11-12: further evidence of genetic heterogeneity of X-linked thrombocytopenia Wendy H. Raskind, Kathy K. Niakan, John Wolff, Mark Matsushita, Ty Vaughan, George Stamatoyannopoulos, Chiaki Watanabe, Jacinda Rios, and Hans D. Ochs From the Departments of Medicine (General Internal Medicine and Medical Genetics) and Pediatrics, University of Washington School of Medicine, Seattle, WA.     Abstract Top Abstract Introduction Materials and methods Results Discussion References X-linked thrombocytopenia with thalassemia (XLTT; Online Mendelian Inheritance in Man [OMIM] accession number 314050) is a rare disorder characterized by thrombocytopenia, platelet dysfunction, splenomegaly, reticulocytosis, and unbalanced hemoglobin chain synthesis. In a 4-generation family, the gene responsible for XLTT was mapped to the X chromosome, short arm, bands 11-12 (band Xp11-12). The maximum lod score possible in this family, 2.39, was obtained for markers DXS8054 and DXS1003, at a recombination fraction of 0. Recombination events observed for XLTT and markers DXS8080 and DXS8023 or DXS991 define a critical region that is less than or equal to 7.65 KcM and contains the gene responsible for the Wiskott-Aldrich syndrome (WAS; OMIM accession number 301000) and its allelic variant X-linked thrombocytopenia (XLT; OMIM accession number 313900). Manifestations of WAS include thrombocytopenia, eczema, and immunodeficiency. In WAS/XLT the platelets are usually small, and bleeding is proportional to the degree of thrombocytopenia. In contrast, in XLTT the platelet morphology is normal, and the bleeding time is disproportionately prolonged. In this study no alteration in the WAS gene was detected by Northern blot or Western blot analysis, flow cytometry, or complimentary DNA dideoxynucleotide fingerprinting or sequencing. As has been reported for WAS and some cases of XLT, almost total inactivation of the XLTT gene-bearing X chromosome was observed in granulocytes and peripheral blood mononuclear cells from 1 asymptomatic obligate carrier. The XLTT carrier previously found to have an elevated : hemoglobin chain ratio had a skewed, but not clonal, X-inactivation pattern favoring activity of the abnormal allele. Clinical differences and results of the mutation analyses make it very unlikely that XLTT is another allelic variant of WAS/XLT and strongly suggest that X-linked thrombocytopenia mapping to band Xp11-12 is a genetically heterogeneous disorder. (Blood. 2000;95:2262-2268) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References In 1977, Thompson et al1 described a family segregating X-linked thrombocytopenia with thalassemia (XLTT; Online Mendelian Inheritance in Man [OMIM] accession number 3140502). This rare disorder is characterized by moderate thrombocytopenia, splenomegaly, reticulocytosis, and unbalanced hemoglobin (Hb) chain synthesis with elevated HbA2 and HbF, which resembles -thalassemia minor. The morphology of platelets and red cells in XLTT is essentially normal as are platelet factor 3 levels, clot retraction, and platelet aggregation. However, platelet dysfunction is evidenced by disproportionately prolonged bleeding times, and affected males manifest petechiae, epistaxis, and easy bruising. Some female carriers also exhibit globin synthesis imbalance and/or mild reticulocytosis. Several disorders associated with thrombocytopenia have been localized to the X chromosome.2,3 Chronic idiopathic intestinal pseudoobstruction (CIIP; OMIM accession number 3000482) is a recessive disorder of gastrointestinal motility that maps to the X chromosome, long arm, band 28 (band Xq28).4 Some CIIP-affected males have chronic thrombocytopenia with large platelets.5,6 The phenotypic spectrum of X-linked dyskeratosis congenital (DKC; OMIM accession number 3050002) includes pigment and nail abnormalities, mucosal leukoplakia, increased risk for malignancies, atresia of the lacrimal ducts, testicular atrophy, anemia, and elevated fetal hemoglobin in addition to thrombocytopenia.7,8 DKC is caused by mutations in the gene encoding dyskerin (DKC1; OMIM accession number 3001262) at band Xq28.9 A syndrome of immunodeficiency with increased immunoglobulin M (IgM) (HIGM1; OMIM accession number 3082302) at band Xq26 is primarily a T-cell disorder caused by mutations in the CD40 ligand gene.10 The thrombocytopenia that may develop in this disorder is likely a manifestation of autoimmunity. Paroxysmal nocturnal hemoglobinuria (PNH), an acquired clonal disorder of multipotential hematopoietic stem cells manifested by complement-mediated hemolysis, results from mutations in the gene at chromosome band Xp22.1, which encodes the Class A phosphatidylinositol glycan (PIGA) gene.11,12 In PNH there is deficient biosynthesis of the glycosylphosphatidylinositol (GPI) anchor and decreased surface expression of multiple GPI-anchored proteins.13,14 It has been suggested that a germline mutation resulting in defects in this biosynthetic pathway would be lethal.15 But it is possible that certain portions of the gene would tolerate a relatively conservative mutation, and this might lead to a modified phenotype. Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT) form a spectrum of disorders resulting from mutations in the WAS protein (WASP) gene at band Xp11-12.16-23 Patients with classic WAS develop severe immunodeficiency, thrombocytopenia, and eczema including a propensity to develop autoimmune disorders and malignancies, while patients with the mildest cases of XLT develop isolated thrombocytopenia. We performed a study to localize the gene for XLTT and to determine whether it represents an allelic variant of another thrombocytopenia syndrome previously described.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Patients The family with XLTT was extensively evaluated in 1977.1 Average platelet counts of 3 affected males, individuals III-5, III-7, and IV-3 (Figure 1), were 77, 76, and 72, respectively (all counts × 109/Lj; normal range, 55 to 90). Platelet survival time measured in 2 of the men was shortened to 3.4 days from the normal range of 8-12 days. Bleeding times were markedly prolonged in all 3 men (greater than 30 minutes); however, platelet aggregation studies with adenosine diphosphate, epinephrine, collagen, and thrombin were all normal. Electronic sizing and smear evaluation revealed occasional platelet enlargement in individual IV-3 but normal platelet volumes in individuals III-5 and III-7. The : chain ratios were 1.5 to 1.8 in individuals III-5 and III-7, respectively, and 1.58 in individual II-4, an obligate carrier. The HbA2 level was mildly elevated at 3.8%-4.4% (normal range: 1.8%-3.4%). Hemoglobin chain synthesis was balanced in all other heterozygotes studied (individuals III-3, IV-6, and IV-8). Unlike the -thalassemia trait, red cell morphology in affected individuals was normal. View larger version (27K): [in this window] [in a new window]   Fig 1. Pedigree and haplotypes of the family with XLTT. Although individual II-1 was not examined, his history of bleeding and bruising with minimal trauma strongly suggest that he was affected. The portion of the chromosome containing the XLTT gene is shown in black. Previously, : globin chain ratios were studied in some members. Individuals in whom an altered hemoglobin chain ratio was detected are denoted by a + sign, and individuals with a normal ratio are denoted by a  sign. DNA and RNA analyses DNA was extracted from leukocytes or Epstein-Barr virus-transformed (EBV-transformed) B-lymphoblastoid cell lines and was amplified by polymerase chain reaction (PCR) in a programmable thermal controller (PTC-100; MJ Research, Watertown, MA) as previously described.24 Primers (Research Genetics, Huntsville, AL) used in the study spanned the X chromosome at distances ranging from 5-14 KcM, and 1 primer of each pair was end labeled with 32 adenosine 5'-triphosphate (ATP) by a T4 kinase reaction. As previously described,25 RNA isolation was performed using a single-step method and (Trizol; Gibco-BRL, Gaithersburg, MD), and reverse transcriptase-PCR (RT-PCR) was performed with a system kit (SuperScript Preamplification System, Gibco-BRL). WAS complementary DNA (cDNA) was amplified in 1 fragment using previously reported primers W-2 and W-1708c21 and PCR (Expand High Fidelity PCR System, Gibco-BRL). PCR products were purified by agarose gel electrophoresis. To screen the amplified WAS cDNA for mutations, we modified the dideoxynucleotide fingerprinting (ddF) method originally designed by Sarkar et al26 as previously described21 (fmol DNA Cycle Sequencing System; Promega, Madison, WI). The resulting PCR products were electrophoresed in 5% polyacrylamide nondenaturing gel at 4°C. To sequence WAS, cDNA was PCR amplified using 4 overlapping primer sets (Table 1) and purified (Nucleospin Extraction Kit; Clontech, Palo Alto, CA). Sequencing was performed on fluorescence-labeled DNA (ABI PRISM BigDyeTerminator Cycle Sequencing Ready Reaction kit; PE Biosystems, Foster City, CA), and electropherograms (Model 373 DNA sequencer; Applied Biosystems) were generated according to manufacturer's instructions. The same primer sets used for PCR amplifications were also used as sequencing primers.                                View this table: [in this window] [in a new window]   Table 1. Primer pairs and PCR conditions for sequencing WAS cDNA Protein analysis For fluorescence-activated cell sorting, 2 × 106 EBV-transformed B-lymphoblastoid cells from individual III-5 and from a normal control were fixed in 1 mL 4% paraformaldehyde and phosphate-buffered saline (PBS) for 15 minutes at room temperature. The cells were then washed twice with PBS and permeabilized with 0.1% Triton X-100/Tris-buffered saline (tris[hydroxymethyl] aminomethane-buffered saline [TBS]) for 5 minutes at room temperature. Cells were washed twice and resuspended in 100 µL PBS containing 1% fetal calf serum and mouse anti-WASP monoclonal antibody (mAb) 3F3.A5 (gift of Dr David Nelson, National Institutes of Health, Bethesda, MD) at a final concentration of 5 µg/mL for 20 minutes on ice. The cells were washed again and then stained with fluorescein isothiocyanate-conjugated (FITC-conjugated) antimouse IgG1 mAb at a dilution of 1:500 for 20 minutes on ice. The cells were then washed and analyzed on a fluorescence-activated cell sorter (FACS) flow cytometer (FACScan; Becton-Dickinson, San Jose, CA). Western blot analysis EBV-transformed cells from affected individuals, III-5 and IV-3, a positive control, and a negative control were suspended at 2.5 × 107 cells/mL in lysis buffer containing 200 µg/mL phenylmethylsulfonyl fluoride, 2 µg/mL aprotinin, and 5 µg/mL leupeptin and kept on ice for 30 minutes. The protein concentration in each lysate was determined by a protein assay kit (Bio-Rad, Hercules, CA). From each sample, 23 µg total protein was electrophoresed through a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred to a membrane (PVDF Immobilon-P; Millipore, Bedford, MA). The membrane was incubated with anti-WASP antibody 503 (1:2000) and anti-Actin antibody (1:500) (Sigma, St. Louis, MO) for 1.5 hours at room temperature. After washing twice with 0.05% TBS Tween/PBS, the membrane was incubated with horseradish peroxidase-conjugated goat antirabbit IgS (Biosource International, Camarillo, CA) at a concentration of 1:1000 for 45 minutes at room temperature. The membrane was then washed 4 times, and the results were visualized by an enhanced chemiluminescent method (Pierce, Rockford, IL). X-inactivation analysis DNA extracted from polymorphonuclear and mononuclear cells was separated by centrifugation through a discontinuous gradient (Ficoll/Hypaque, Sigma) and evaluated for methylation patterns at the human androgen receptor alpha (HUMARA) locus by a modification of the method published by Allen et al.27 Genomic DNA (1 µg) was digested overnight at 37°C in 40-mL volumes containing 80 units HpaII at a concentration of 50 units/mL (New England Biolabs, Beverly, MA) and 10 units RsaI (Pharmacia Biotech, Uppsala, Sweden) or RsaI alone. This solution (4 µL) was PCR amplified in 20-µL volumes containing 200 µmol/L dNTP (a'-deoxynucleoside 5'-triphosphate) and 0.5 units polymerase (AmpliTaq, Perkin Elmer) at a final concentration of 3.7 mmol/L magnesium dichloride (MgCl2) in addition to 0.38 µmol/L each of the forward and reverse primers end labeled with 0.016 MBq (0.45 µCi) 32ATP. The following thermal profile was used: initial denaturation for 3 minutes at 94°C; 30 cycles each of 45 seconds at 94°C, 30 seconds at 65°C, and 30 seconds at 72°C; and a final 6-minute incubation at 72°C. Amplified products were electrophoresed for 4 hours at 70 W through 6% polyacrylamide gels containing 7 mol/L urea and 30% formamide. Dried gels were autoradiographed, and the relative band intensities in the RsaI/HpaII- and RsaI-digested lanes were quantitated by a scanning densitometer (Hoefer GS300 with GS370 software; Hoefer Scientific Instruments, San Francisco, CA). Clonal female DNA was included to evaluate completeness of HpaII digestion. Linkage analysis Power analysis and 2-point linkage analyses were performed with the SLINK and MLINK subprograms of the LINKAGE package version 5.0,28 as implemented in FASTLINK for DOS (version 3.0P).29 X-linked recessive inheritance with a gene frequency of 0.0001 for the disease allele was assumed for XLTT. Allele sizes and frequencies and the order of the marker loci were obtained from the Genome Database [GDB].30 Sex-averaged map distances are described in Broman et al31 and are available from the Marshfield website.32 When possible, allele sizes on the autoradiographs were standardized by comparison to DNAs from CEPH families 1331 and 1347.33     Results Top Abstract Introduction Materials and methods Results Discussion References Mapping the XLTT syndrome to band Xp11-12 Simulation studies suggested that a maximum lod score of 2.39 at a recombination fraction of  = 0 could be obtained with the samples available. For an X-linked disorder, a lod score of 2 provides evidence at approximately P = .05 for linkage. Genotypes were then evaluated for polymorphic markers spanning the X chromosome (Table 2). A lod score of 2.39 was obtained at  = 0 for markers DXS8054 and DXS1003. After locating this region of interest, finer scale mapping was performed, and haplotypes were constructed. Recombination events were observed for the XLTT gene and markers DXS8080 and DXS8023 or DXS991 (Figure 1). Because carrier III-3 is homozygous for DXS8023, the proximal breakpoint could not be more specifically placed. These recombinations define a critical region that is less than or equal to 7.65 KcM on band Xp11-12. This region contains the gene responsible for WAS.                                View this table: [in this window] [in a new window]   Table 2. Two-point lod scores for linkage of XLTT to X chromosome markers Exclusion of the WAS gene as the cause of XLTT Dideoxynucleotide fingerprinting, which combines single-base dideoxy sequencing and the single-strand conformation polymorphism assay, was used as the initial mutation screen. The dideoxy component detects the substitution, addition, or deletion of the single base, and the single-strand conformation polymorphism component detects changes in other base pairs (bp). The ddF protocol used would have detected mutations affecting nucleotides A and T, and only guanine/cytosine transitions might have been missed. No alterations were seen in the ddF pattern of WAS cDNA from the B cell lines of affected male carriers III-5 and IV-3. Exons 1-12 were then sequenced from cDNA, thereby revealing only the wild type sequence. Finally, WAS from these affected XLTT males was analyzed by Western blot (Figure 2) and FACS (not shown). Western blot analysis revealed that WASP was of normal size, and both assays detected normal amounts of WASP. View larger version (33K): [in this window] [in a new window]   Fig 2. Evaluation of WASP by Western blot analysis. Western blot evaluations are given for the following: WASP and actin from 2 affected males with XLTT, an unrelated normal control, and an individual with classic WAS. The patient with classic WAS carries a nonsense mutation in the WAS gene, which results in absence of detectable WASP. X-inactivation studies in obligate carriers of XLTT X-inactivation patterns were assessed by evaluating the methylation status of cytosine resides near a highly polymorphic trinucleotide repeat sequence in the HUMARA locus (Figure 3). The allele on the inactive X chromosome is highly methylated and resists digestion by methylation-sensitive restriction endonucleases such as HpaII, whereas the allele on the active X chromosome is digested. Therefore, only inactive X chromosomes contribute alleles for the PCR amplification step that follows. In heterozygous women, the relative proportion of inactive maternally- and paternally-derived X chromosomes can be compared. Of the 4 obligate heterozygous females sampled, 1 (carrier V-1) was homozygous for HUMARA and, therefore, could not be evaluated. Marked skewing of the X-inactivation pattern was observed in carrier III-3; the allele carried by affected males was resistant to HpaII digestion, which shows that it is uniformly inactivated. The pattern in carrier II-4 was biased in the opposite direction; the ratio was 67:33, favoring activity of the abnormal XLTT gene-bearing chromosome. Skewing was not observed in the X-inactivation pattern of carrier IV-8. View larger version (56K): [in this window] [in a new window]   Fig 3. Evaluation of X-inactivation patterns in 4 obligate carriers of XLTT. DNA digested with RsaI (lanes marked ) or RsaI and HpaII (lanes marked +) was PCR amplified using primers for HUMARA. Only alleles on inactive X chromosomes are amplified following HpaII digestion. The allele carried by affected males is denoted A (data not shown). HUMARA lies just distal to the minimal region containing XLTT, and there were no recombinations between XLTT and HUMARA in individuals III-3, III-5, or IV-3. Although carriers IV-8 and V-1 were not included in the linkage analysis, they each must have inherited the X chromosome from their affected fathers, without any further recombinations.     Discussion Top Abstract Introduction Materials and methods Results Discussion References Localization of XLTT to the region of the X chromosome containing the gene responsible for WAS/XLT suggested that XLTT might be another allelic variant of this syndrome. However, there are substantial clinical differences between the XLTT and WAS/XLT syndromes. In XLTT, platelet morphologies are normal and the bleeding times are disproportionately prolonged, whereas in WAS/XLT, the platelets are usually small, and bleeding times are proportional to the degree of thrombocytopenia.23 The failure to find an alteration in WAS DNA, RNA, or protein from XLTT males by a variety of approaches provides strong evidence against inclusion of XLTT in the WAS/XLT spectrum. These data provide evidence for additional genetic heterogeneity of XLT syndromes and suggest that band Xp11-12 contains more than 1 gene involved in platelet production and/or survival. Out of 4 XLTT obligate carrier women evaluated, 1 manifested some characteristics of XLTT. Because females are mosaics of cells bearing active paternally- and maternally-derived X chromosomes, they are much less likely to show manifestations of X-linked recessive disorders than males. The process of X inactivation occurs early in embryogenesis and is random with respect to the choice of X chromosome in each cell, and the activity status is thereafter stably maintained during mitosis.34 Expression of a variety of X-linked recessive diseases in carrier females35-37 has been attributed to the chance occurrence of markedly skewed X inactivation of the chromosome bearing the normal allele. However, a minority of cases may result from mutation in the XIST gene.38 In contrast, in some disorders a markedly skewed pattern of X inactivation is seen in cells from most carrier females. For instance, the pattern in platelets, granulocytes, and lymphocytes of women carrying the WAS gene is skewed so that essentially all cells have the abnormal X chromosome inactivated.39-43 The situation is less clear for XLT. Some investigators report a skewed pattern in carriers, whereas others find a random pattern in some cell lineages.44,45 The most cogent explanation for the skewed pattern is postinactivation selection that favors cells bearing the normal allele in the active state in tissues in which the gene is expressed.46-48 Female carriers are usually asymptomatic, but females affected with WAS/XLT have been identified, and in these patients, the mutant WAS allele was found to be active.36 Unlike WAS, there is not a consistent pattern of selection for the X chromosome bearing the normal XLTT allele. As seen in carriers of the WAS gene, almost total inactivation of the XLTT gene-bearing chromosome was observed in 1 clinically unaffected obligate carrier (carrier III-3). However, a random X-inactivation pattern was found in the other informative unaffected obligate carrier (carrier IV-8). In contrast, a skewed pattern favoring activity of the chromosome bearing the abnormal XLTT allele was demonstrated in the 1 carrier previously shown to have an elevated : hemoglobin chain ratio (carrier II-4). Perhaps this individual manifests only mild clinical features of XLTT because a portion of her hematopoietic cells express a normal XLTT product. Thrombocytopenia, elevated fetal hemoglobin levels, and thalassemia are features of several X-linked disorders. With the exception of WAS, these disorders do not map to the critical region for the XLTT gene. However, information about their structure or function may help in identifying the gene. DKC1 contains 2 TruB pseudouridine synthase motifs, multiple phosphorylation sites, and a carboxy-terminal lysine-rich domain. DKC1 is predicted to be a nuclear protein involved in the cell cycle and in nucleolar function.9,49 The CD40 ligand is a type 2 glycoprotein expressed as a homotrimer on the membranes of activated T cells.10 WAS encodes a cytoplasmic signal transduction adaptor protein containing proline-rich domains that bind SH3-domain-containing proteins, a pleckstrin homology (PH) domain, and a guanosine 5'-triphosphatase-binding (GTPase-binding) domain.22 PH domains are known to mediate binding of cytoplasmic proteins to membrane phospholipids,50,51 and SH3-domain-containing proteins are involved in protein-protein interactions that mediate signal transduction cascades and may be involved in cytoskeletal regulation.52,53 GTPases function in transcriptional activation, maintenance of the actin cytoskeleton, and cell cycle regulation.54,55 The mechanism of thrombocytopenia in WAS/XLT is not entirely understood, but it appears that the amino-terminal region of WASP is required for platelet production. Mutations in the PH domain result in a phenotype of XLT with predominantly platelet abnormalities and very mild or no symptoms of immune deficiency.22,56 Hereditary persistence of fetal hemoglobin (HPFH) is a genetically heterogeneous condition. Although most cases are associated with point-mutations or deletions in the -globin cluster,57 unlinked loci have been shown to influence HgF levels in both healthy individuals and patients with sickle cell anemia.58-60 One of these factors is the F cell locus (FCP1, OMIM accession number 3054352) at band Xp22.2-22.3.61,62 The gene at this locus is implicated in Swiss-type HPFH, but it has not yet been cloned. There is precedence for thalassemia to be part of an X-linked syndrome. Although the -globin locus maps to chromosome 16,63 the ATR-X syndrome, which is characterized by mental retardation and -thalassemia, is caused by a mutation in the helicase gene XH2 in band Xq13.64 Among other activities, helicases regulate gene expression.65 When mutated, the ATRX gene selectively down-regulates the -globin locus but not the -globin locus.66 The study of this family with XLTT suggests that there is an X-linked locus which plays a role similar to the role of ATR-X. It is likely that this locus, possibly coding for a helicase or other regulator of transcription, is mutated in XLTT. Aside from the WAS gene, the critical region on band Xp11-12 contains at least 30 known genes and many more expressed sequence tags that can be investigated as candidates for XLTT.67 Many of these transcripts are expressed in spleen cells, but it is not known whether the transcripts are tissue specific. The following genes can be omitted from further consideration because they have functions and/or expression patterns unlikely to produce the phenotype of XLTT: MAOA, MAOB, NDP, RGN, KIAA0215, ARAF1, RBM3, KCND1, PFC, SYP, SYN1, CLCN5, AKAP82, PLP2, HADH2, GJA1, FGD1, TRO, and ALAS2. Of potential interest are the genes UHX1, UBE1, PCTK1, TIMP1, and HDAC6 and a number of zinc finger genes. Ubiquitination of proteins is important for many cellular processes including DNA repair, cell cycle control, and peroxisome synthesis.68 There are 2 genes involved in the ubiquitin system that map to the critical region: UH × 1, a ubiquitin-specific protease,69 and UBE1, the ubiquitin-activating enzyme E1, which catalyzes the first step in ubiquitin conjugation.70,71 The PCTK1 gene is a member of a family of cdc2-related serine/threonine-specific protein kinases.72 PCTK1 has wide expression, although it is most highly expressed in testis and brain. UBE1 and PCTK1, which are contiguous genes, both escape X inactivation.73 The gene for the glycoprotein growth factor tissue inhibitor of metalloproteinase 1 (TIMP1) is particularly suitable as a candidate for triggering XLTT. TIMP1 is synthesized in and secreted by platelets and, as suggested by its earlier designation for erythroid potentiating activity (EPA), it belongs to a class of molecules involved in erythropoeisis.74 To date, mutations in the UBE1, UH × 1, and TIMP genes have been implicated in retinal disorders, but given their expression patterns and/or function it is reasonable to speculate that other organ systems may be affected by mutations in these genes. Several zinc finger protein family genes also lie in this region: ZNF41, ZNF21, ZNF81, ZNF157, and GATA1.75 Zinc fingers mediate transcriptional activity by recognizing and binding to guanine/cytosine-rich sequences in the control regions of a wide variety of cellular genes.76 The effects may be tissue-specific or ubiquitous and are modulated through interactions with cofactor proteins. Given the wide-reaching importance of these transcription factors in development, knockout mutations are often embryonic lethals.77 However, viable transgenic models have been created by limiting expression of the mutation to specific lineages.78 Histone deacetylases also function as regulators of transcription by modulating the nuclear proteins that bind DNA.79 The histone deacetylase 6 gene (HDAC6), which maps to the critical region for XLTT, is a recently cloned serine/threonine protein kinase whose function is not well characterized.80 The 10 genes discussed above will be evaluated in the future for sequence alterations in XLTT. Consensus sequences for functional subportions of the genes involved in the disorders discussed above may aid in identifying additional candidate genes for study.     Acknowledgments We appreciate the participation of the family afflicted with XLTT, without whose cooperation this work would not have been possible. We are grateful to Dr David Nelson of the National Institutes of Health, Bethesda, MD, for the generous gift of anti-WASP mAb 3F3.A5.     Footnotes Submitted August 2, 1999; accepted November 29, 1999. Supported in part by grants CA16448 (W.H.R., M.M., and J.W.), HD17427 (H.D.O.), and 5R37 HL20899 (G.S.) from the National Institutes of Health, Bethesda, MD; grant FY98-418 (H.D.O.) from the March of Dimes Birth Defects Foundation, White Plains, NY; and a grant from the DeJoria Wiskott-Aldrich Research Fund, Beverly Hills, CA (H.D.O.). Reprints: Wendy H. Raskind, Department of Medicine, Box 357720, University of Washington, Seattle, WA 98195; e-mail: wendyrun{at}u.washington.edu. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Thompson AR, Wood WG, Stamatoyannopoulos G. X-linked syndrome of platelet dysfunction, thrombocytopenia, and imbalanced globin chain synthesis with hemolysis. Blood. 1997;50:303[Abstract/Free Full Text]. 2. Online Medelian Inheritance in Man (OMIM). Available at: http://www.ncbi.nlm.nih.gov/Omim. Accessed June 30, 1999. 3. Dib C, Faure S, Fizames C, et al. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 1996;380:152[Medline] [Order article via Infotrieve]. 4. Auricchio A, Brancolini V, Casari G, et al. The locus for a novel syndromic form of neuronal intestinal pseudoobstruction maps to Xq28. Am J Hum Genet. 1996;58:743[Medline] [Order article via Infotrieve]. 5. Pollock I, Holmes SJK, Patton MA, Hamilton PA, Stacey TE. Congenital intestinal pseudo-obstruction associated with a giant platelet disorder. J Med Genet. 1991;28:495[Abstract/Free Full Text]. 6. FitzPatrick DR, Strain L, Thomas AE, et al. Neurogenic chronic idiopathic intestinal pseudo-obstruction, patent ductus arteriosus, and thrombocytopenia segregating as an X linked recessive disorder. J Med Genet. 1997;34:666[Abstract/Free Full Text]. 7. Davidson HR, Connor JM. Dyskeratosis congenita. J Med Genet. 1988;25:843[Free Full Text]. 8. Reichel M, Grix AC, Isseroff RR. Dyskeratosis congenita associated with elevated fetal hemoglobin, X-linked ocular albinism, and juvenile-onset diabetes mellitus. Pediatr Derm. 1992;9:103. 9. Heiss NS, Knight SW, Vulliamy TJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet. 1998;19:32[Medline] [Order article via Infotrieve]. 10. Aruffo A, Farrington M, Hollenbaugh D, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993;72:291[Medline] [Order article via Infotrieve]. 11. Rosse WF. Paroxysmal nocturnal hemoglobinuria: the biochemical defects and the clinical syndrome [review]. Blood. 1989;3:192. 12. Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993;259:1318[Abstract/Free Full Text]. 13. Mahoney JF, Urakaze M, Hall S, et al. Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. Blood. 1992;79:1400[Abstract/Free Full Text]. 14. Hirose S, Ravi L, Prince GM, et al. Synthesis of mannosylglucosaminylinositol phospholipids in normal but not paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci U S A. 1992;89:6025[Abstract/Free Full Text]. 15. Rosse WF. The glycolipid anchor of membrane surface proteins. Semin Hematol. 1993;30:219[Medline] [Order article via Infotrieve]. 16. Notarangelo L, Parolini O, Faustini R, Porteri V, Albertini A, Ugazio A. Presentation of Wiskott-Aldrich syndrome as isolated thrombocytopenia. Blood. 1991;77:1125[Free Full Text]. 17. Standen G. Wiskott-Aldrich syndrome: a multidisciplinary disease. J Clin Pathol. 1991;44:979[Free Full Text]. 18. Derry JM, Kerns JA, Weinberg KI, et al. WASP gene mutations in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Hum Mol Genet. 1995;4:1127[Abstract/Free Full Text]. 19. Kolluri R, Shehabeldin A, Peacocke M, et al. Identification of WASP mutations in patients with Wiskott-Aldrich syndrome and isolated thrombocytopenia reveals allelic heterogeneity at the WAS locus. Hum Mol Genet. 1995;4:1119[Abstract/Free Full Text]. 20. Villa A, Notarangelo L, Macchi P, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet. 1995;9:414[Medline] [Order article via Infotrieve]. 21. Zhu Q, Zhang M, Blaese RM, et al. The Wiskott-Aldrich syndrome and X-linked thrombocytopenia are caused by mutations of the same gene. Blood. 1995;86:3797[Abstract/Free Full Text]. 22. Zhu Q, Watanabe C, Liu T, et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood. 1997;90:2680[Abstract/Free Full Text]. 23. Ochs H. The Wiskott-Aldrich syndrome. Semin Hematol. 1998;35:332[Medline] [Order article via Infotrieve]. 24. Raskind WH, Conrad EU, Chansky H, Matsushita M. Loss of heterozygosity in chondrosarcomas for markers linked to hereditary multiple exostoses loci on chromosomes 8 and 11. Am J Hum Genet. 1995;56:1132[Medline] [Order article via Infotrieve]. 25. Zhu Q, Zhang M, Rawlings DJ, et al. Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinema (XLA). J Exp Med. 1994;180:461[Abstract/Free Full Text]. 26. Sarkar G, Yoon H-S, Sommer SS. Dideoxy fingerprinting (ddF): a rapid and efficient screen for the presence of mutations. Genomics. 1992;13:441[Medline] [Order article via Infotrieve]. 27. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51:1229[Medline] [Order article via Infotrieve]. 28. Lathrop GM, Lalouel JM, Ott J. Strategies for multilocus linkage analysis in humans. Proc Natl Acad Sci U S A. 1984;81:3443[Abstract/Free Full Text]. 29. Schaffer AA, Gupta K, Shriram K, Cottingham RW. Avoiding recomputation in linkage analysis. Hum Hered. 1994;44:225[Medline] [Order article via Infotrieve]. 30. GENOME DATABASE (GDB) [database online]. Available at: http://www.gdb.org. 31. Broman KW, Murray JC, Sheffield VC, White RL, Weber JL. Comprehensive human genetic maps: individual and sex-specific variation in recombination. Am J Hum Genet. 1998;63:861[Medline] [Order article via Infotrieve]. 32. Comprehensive Human Genetic Maps. Available at: http://www.marshmed.org/genetics. 33. Dausset J, Cann H, Cohen D, Lathrop M, Lalouel JM, White R. Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome. Genomics. 1990;6:575[Medline] [Order article via Infotrieve]. 34. Gartler SM, Dyer KA, Goldman MA. Mammalian X chromosome inactivation. Mol Genet Med. 1992;2:121[Medline] [Order article via Infotrieve]. 35. Yoshioka M, Yorifuji T, Mituyoshi I. Skewed X inactivation in manifesting carriers of Duchenne muscular dystrophy. Clin Genet. 1998;53:102[Medline] [Order article via Infotrieve]. 36. Parolini O, Ressmann G, Haas OA, et al. X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med. 1998;338:291[Free Full Text]. 37. Tanner SM, Orstavik KH, Kristiansen M, et al. Skewed X-inactivation in a manifesting carrier of X-linked myotubular myopathy and in her non-manifesting carrier mother. Hum Genet. 1999;104:249[Medline] [Order article via Infotrieve]. 38. Plenge RM, Hendrich BD, Schwartz C, et al. A promoter mutation in the XIST gene in two unrelated families with skewed X-chromosome inactivation. Nat Genet. 1997;17:353[Medline] [Order article via Infotrieve]. 39. Gealy WJ, Dwyer JM, Harley JB. Allelic exclusion of glucose-6-phosphate dehydrogenase in platelets and T lymphocytes from a Wiskott-Aldrich carrier. Lancet. 1980;1:63[Medline] [Order article via Infotrieve]. 40. Fearon ER, Kohn DB, Winkelstein JA, Vogelstein B, Blaese RM. Carrier detection in the Wiskott-Aldrich syndrome. Blood. 1988;56:1735. 41. Greer WL, Kwong PC, Peacocke M, Ip P, Rubin LA, Siminovitch KA. X-chromosome inactivation in the Wiskott-Aldrich syndrome: a marker for detection of the carrier state and identification of cell lineages expressing the gene defect. Genomics. 1989;4:60[Medline] [Order article via Infotrieve]. 42. Wengler G, Gorlin JB, Williamson JM, Rosen FS, Bing DH. Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome. Blood. 1995;85:2471[Abstract/Free Full Text]. 43. Ariga T, Yamada M, Wada T, Saitoh S, Sakiyama Y. Detection of lymphocytes and granulocytes expressing the mutant WASP message in carriers of Wiskott-Aldrich syndrome. Br J Haematol. 1999;104:893[Medline] [Order article via Infotrieve]. 44. Puck JM, Siminovitch KA, Poncz M, Greenberg CR, Rottem M, Conley ME. Atypical presentation of Wiskott-Aldrich syndrome: diagnosis in two unrelated males based on studies of maternal T cell X chromosome inactivation. Blood. 1990;75:2369[Abstract/Free Full Text]. 45. De Saint-Basile G, Schlegel N, Caniglia M, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome: similar regional assignment but distinct X-inactivation pattern in carriers. Ann Hematol. 1991;63:107[Medline] [Order article via Infotrieve]. 46. Belmont JW. Genetic control of X inactivation and processes leading to X-inactivation skewing. Am J Hum Genet. 1996;58:1101[Medline] [Order article via Infotrieve]. 47. Migeon BR. Non-random X chromosome inactivation in mammalian cells. Cytogenet Cell Genet. 1998;80:142[Medline] [Order article via Infotrieve]. 48. Migeon BR, Haisley-Royster C. Familial skewed X inactivation and X-linked mutations: unbalanced X inactivation is a powerful means to ascertain X-linked genes that affect cell proliferation. Am J Hum Genet. 1998;62:1555[Medline] [Order article via Infotrieve]. 49. McGrath JA. Dyskeratosis congenita: new clinical and molecular insights into ribosome function. Lancet. 1999;353:1204[Medline] [Order article via Infotrieve]. 50. Saraste M, Hyvönen M. Pleckstrin homology domains: A fact file. Curr Opin Struct Biol. 1995;5:403[Medline] [Order article via Infotrieve]. 51. Hyvönen M, Macias MJ, Nilges M, Oschkinat H, Saraste M, Wilmanns M. Structure of the binding site for inositol phosphates in a PH domain. EMBO J. 1995;14:4676[Medline] [Order article via Infotrieve]. 52. Haffner C, Jarchau T, Reinhard M, et al. Molecular cloning, structural analysis and functional expression of the proline-rich focal adhesion and microfilament-associated protein VASP. EMBO J. 1995;14:19[Medline] [Order article via Infotrieve]. 53. Reinhard M, Giehl K, Abel K, et al. The proline-rich focal adhesion and microfilament protein VASP is a ligand for profilins. EMBO J. 1995;14:1583[Medline] [Order article via Infotrieve]. 54. Symons M, Derry JM, Karlak B, et al. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell. 1996;84:723[Medline] [Order article via Infotrieve]. 55. Aspenstrom P, Lindberg U, Hall A. Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome. Curr Biol. 1996;6:70[Medline] [Order article via Infotrieve]. 56. Miki H, Nonoyama S, Zhu Q, Aruffo A, Ochs HD, Takenawa T. Tyrosine kinase signaling regulates Wiskott-Aldrich syndrome protein function, which is essential for megakaryocyte differentiation. Cell Growth Differ. 1997;8:195[Abstract]. 57. Forget GB. Molecular basis of hereditary persistence of fetal hemoglobin. Ann N Y Acad Sci. 1998;850:38[Medline] [Order article via Infotrieve]. 58. Boyer SH, Dover GJ, Serjeant GR, et al. Production of F cells in sickle cell anemia: regulation by a genetic locus or loci separate from the beta-globin gene cluster. Blood. 1984;64:1053[Abstract/Free Full Text]. 59. Miyoshi K, Kaneto Y, Kawai H, et al. X-linked dominant control of F-cells in normal adult life: characterization of the Swiss type as hereditary persistence of fetal hemoglobin regulated dominantly by gene(s) on the X chromosome. Blood. 1988;72:1854[Abstract/Free Full Text]. 60. Seltzer WK, Abshire TC, Lane PA, Roloff JS, Githens JH. Molecular genetic studies in black families with sickle cell anemia and unusually high levels of fetal hemoglobin. Hemoglobin. 1992;16:363[Medline] [Order article via Infotrieve]. 61. Dover GJ, Smith KD, Chang YC, et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood. 1992;80:816[Abstract/Free Full Text]. 62. Chang YC, Smith KD, Moore RD, Serjeant GR, Dover GJ. An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, beta-globin haplotypes, alpha-globin gene number, gender, and age. Blood. 1995;85:1111[Abstract/Free Full Text]. 63. Deisseroth A, Nienhuis A, Turner P, et al. Localization of the human alpha globin structural gene to chromosome 16 in somatic cell hybrids by molecular hybridization assay. Cell. 1977;12:205[Medline] [Order article via Infotrieve]. 64. Gibbons RJ, Picketts DJ, Villard L, Higgs DR. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with -thalassemia (ATR-X syndrome). Cell. 1995;80:837[Medline] [Order article via Infotrieve]. 65. Ellis NA. DNA helicases in inherited human disorders. Curr Opin Genet Dev. 1997;7:354[Medline] [Order article via Infotrieve]. 66. Picketts DJ, Higgs DR, Bachoo S, Blake DJ, Quarrell OWJ, Gibbons RJ. ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome. Hum Mol Genet. 1996;5:1899[Abstract/Free Full Text]. 67. Gyapay G, Schmitt K, Fizames C, et al. A radiation hybrid map of the human genome. Hum Mol Genet. 1996;5:339[Abstract/Free Full Text]. 68. Schwartz AL, Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med. 1999;50:57[Medline] [Order article via Infotrieve]. 69. Swanson DA, Freund CL, Ploder L, McInnes RR, Valle D. A ubiquitin C-terminal hydrolase gene on the proximal short arm of the X chromosome: implications for X-linked retinal disorders. Hum Mol Genet. 1996;5:533[Abstract/Free Full Text]. 70. Handley PM, Mueckler M, Siegel NR, Ciechanover A, Schwartz AL. Molecular cloning, sequence, and tissue distribution of the human ubiquitin-activating enzyme E1. Proc Nat Acad Sci. U S A 1991;88:258[Abstract/Free Full Text]. 71. Zacksenhaus E, Sheinin R. Molecular cloning of human A1S9 locus: an X-linked gene essential for progression through S phase of the cell cycle. Somat Cell Mol Genet. 1989;15:545[Medline] [Order article via Infotrieve]. 72. Meyerson M, Enders GH, Wu C-L, et al. A family of human cdc2-related protein kinases. EMBO J. 1992;11:2909[Medline] [Order article via Infotrieve]. 73. Carrel L, Clemson CM, Dunn JM, et al. X inactivation analysis and DNA methylation studies of the ubiquitin activating enzyme E1 and PCTAIRE-1 genes in human and mouse. Hum Mol Genet. 1996;5:391[Abstract/Free Full Text]. 74. Huebner K, Isobe M, Gasson JC, Golde DW, Croce CM. Localization of the gene encoding erythroid-potentiating activity to chromosome region Xp11.1-Xp11.4. Am J Hum Genet. 1986;38:819[Medline] [Order article via Infotrieve]. 75. Knight JC, Grimaldi G, Thiesen HJ, Bech-Hansen NTM, Coleman MP. Clustered organization of Kruppel zinc-finger genes at Xp11.23, flanking a translocation breakpoint at OATL1: a physical map with locus assignments for ZNF21, ZNF41, ZNF81 , and ZLK1. Genomics. 1994;21:180[Medline] [Order article via Infotrieve]. 76. Cook T, Gebelein B, Urrutia R. Sp1 and its likes: biochemical and functional predictions for a growing family of zinc finger transcription factors. Ann NY Acad Sci. 1999;880:94[Medline] [Order article via Infotrieve]. 77. Marin M, Karis A, Visser P, Grosveld F, Philipsen S. Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell. 1997;89:619[Medline] [Order article via Infotrieve]. 78. Shivdasani RA, Fujiware Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;6:3965. 79. Wolffe AP. Histone deacetylase: a regulator of transcription. Science. 1996;272:371[Medline] [Order article via Infotrieve]. 80. Grozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci U S A. 1999;96:4868[Abstract/Free Full Text]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Y. Jin, C. Mazza, J. R. Christie, S. Giliani, M. Fiorini, P. Mella, F. Gandellini, D. M. Stewart, Q. Zhu, D. L. Nelson, et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation Blood, December 15, 2004; 104(13): 4010 - 4019. [Abstract] [Full Text] [PDF] C. Yu, K. K. Niakan, M. Matsushita, G. Stamatoyannopoulos, S. H. Orkin, and W. H. Raskind X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction Blood, August 28, 2002; 100(6): 2040 - 2045. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Raskind, W. H. Articles by Ochs, H. D. Search for Related Content PubMed PubMed Citation Articles by Raskind, W. H. Articles by Ochs, H. D. Related Collections Hematopoiesis and Stem Cells Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020